Context Therapeutics litigation ends with $850,000 mootness fee paid by provider

• Delaware Chancery Court on March 11, 2026 entered consent judgment in stockholder class action filed Feb. 4, 2026 against Context Therapeutics and its directors.
• Judgment found charter provisions on three-year director terms and for-cause removal invalid and unenforceable.
• Context filed certificate of correction March 11, 2026 removing invalid provisions, triggering dismissal with prejudice while court retained jurisdiction over mootness fee.
• Court on April 30, 2026 ordered USD 850,000 mootness fee to plaintiff counsel, without reviewing entitlement or amount.
• Third-party service provider paid fee May 1, 2026 under letter agreement; case closure tied to quorum at June 24, 2026 annual meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-029323), on May 01, 2026, and is solely responsible for the information contained therein.